Charles River Laboratories International, Inc. cash flow to debt ratio of 24.06% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Charles River Laboratories International, Inc.'s free cash flow has increased 3.37% from $501.61M last year to $518.49M, signaling increasing performance

Charles River Laboratories International, Inc.'s debt to equity ratio is 0.88, which means that the company's assets are unhealthy financed, signaling financial risk.

Charles River Laboratories International, Inc.'s debt has increased relative to shareholder equity from 0.79 last year to 0.88 today, signaling weakened financials

Charles River Laboratories International, Inc. has a net debt to EBITDA ratio of 6.94x, which exceeds the 3.00x threshold, indicating high leverage and potential financial risk

Charles River Laboratories International, Inc.'s interest coverage ratio of 5.14 indicates that earnings with good margin can cover interest payments on company debt

Charles River Laboratories International, Inc.'s profit margin was 0.25% last year and is 1.01% this year, signaling increasing performance

Charles River Laboratories International, Inc.'s short-term assets of $1.45B exceed its short-term liabilities of $1.12B

Charles River Laboratories International, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Charles River Laboratories International, Inc.'s return on equity of 1.32%, is lower than 15.00%, indicating bad performance

Charles River Laboratories International, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Charles River Laboratories International, Inc. had positive net income in 4 out of 5 years, indicating stable and consistent earnings

Charles River Laboratories International, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Charles River Laboratories International, Inc. has a free cash flow yield of 3.21%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Charles River Laboratories International, Inc.'s yearly earnings has decreased 1.50K% since last year from $10.30M to $-144.34M, signaling decreasing performance

Charles River Laboratories International, Inc.'s yearly revenue has decreased 0.85% since last year from $4.05B to $4.02B, signaling decreasing performance

ROIC -3.76% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Charles River Laboratories International, Inc.'s 3-year revenue CAGR of 0.33% is positive, indicating growing revenue over the past 3 years

Charles River Laboratories International, Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Charles River Laboratories International, Inc. had positive ROE in 4 out of 5 years, indicating consistent and reliable returns on equity

Charles River Laboratories International, Inc. is overvalued relative to its fair value price of 164.72 based on Base Cash Flow Valuation (DCF) model

Charles River Laboratories International, Inc. has an earnings yield of 0.30%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

Charles River Laboratories International, Inc. is overvalued relative to its fair value price of 0.49 based on Base EBITDA Valuation model

Charles River Laboratories International, Inc. has an EV/EBITDA ratio of 46.31x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

Charles River Laboratories International, Inc. is overvalued relative to its fair value price of 218.80 based on Base Earnings Fair Value model

Charles River Laboratories International, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Charles River Laboratories International, Inc. has a price-to-book ratio of 4.93x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Charles River Laboratories International, Inc. has a price-to-sales ratio of 4.06x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue